# A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

> **NCT02059616** · PHASE2 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 384 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Amlodipine 5mg
- **DRUG:** Amlodipine 10mg
- **DRUG:** Candesartan Cilexetil 8mg
- **DRUG:** Candesartan cilexetil 16mg

## Key facts

- **NCT ID:** NCT02059616
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02059616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02059616, "A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02059616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*